An observational study in Meningioma of Brain, sponsored by Sohag University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Sohag University · Observational
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma and associate its expression with certain clinical and pathological paramaters as age, sex of the patients, site (right or left and location), size, diagnosis, WHO grade, if there is bone invasion, if there is necrosis and vascular invasion.
Meningiomas are the most common primary central nervous system (CNS) tumors. Since the PHH3 was reported to be unique to mitosis, the anti-PHH3 antibody was being increasingly studied as a proliferation marker.
50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case.
The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin \& Eosin stained sections to confirm the diagnosis and to detect the histopathological type and grade of each tumor.
Another sliced tissue sections will be immunohistochemically stained with PHH3 monoclonal antibodies and assess its expression by counting positive mitotic nuclei. Correlation of PHH3 proliferative index with WHO histological grade and other clinicopathological parameters.
255 studies on the registry are indexed under Meningioma; 85 are open to participants now.
This study's enrollment of 50 is below the median of 133 across 56 observational studies indexed under Meningioma.
Browse Meningioma studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Fifty (50) cases of meningioma will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) confirmed meningioma cases. 2) Cases classified according to WHO CNS5 (2021). 3) Tissue blocks with sufficient material. 4) Specimens with sufficient clinical data.
-
Exclusion Criteria:
1) Tissue blocks with insufficient, destroyed or necrotic material. 2) Specimens with insufficient clinical data.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fifty (50) cases of meningioma will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Biological: Immunohistochemical staining
Immunohistochemical staining of paraffin embedded blocks of meningioma tissues by PHH3 monoclonal antibodies and assess its expression by counting positive mitotic nuclei. Correlation of PHH3 proliferative index with WHO histological grade and other clinicopathological parameters.
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma.
PHH3 expression was evaluated by immunohistochemistry in meningioma specimens and scored according to the percentage of tumor cells showing positive nuclear staining. Expression was categorized into grade 1,2,3 for statistical analysis.
Time frame: 6 months
Age
Assessment of the association between PHH3 immunohistochemical expression and age subgroups
Time frame: 6 months
Sex
Assessment of the association between PHH3 immunohistochemical expression and sex
Time frame: 6 months
Tumor site
Assessment of the association between PHH3 immunohistochemical expression and tumor site
Time frame: 6 months
Plan to share: Undecided — Not decided yet
No publications or documents are linked to this record.
Ran from Sep 2026 to primary completion in Oct 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.